AU2002349784A8 - Nf-kappab activating genes - Google Patents

Nf-kappab activating genes

Info

Publication number
AU2002349784A8
AU2002349784A8 AU2002349784A AU2002349784A AU2002349784A8 AU 2002349784 A8 AU2002349784 A8 AU 2002349784A8 AU 2002349784 A AU2002349784 A AU 2002349784A AU 2002349784 A AU2002349784 A AU 2002349784A AU 2002349784 A8 AU2002349784 A8 AU 2002349784A8
Authority
AU
Australia
Prior art keywords
activating genes
kappab
kappab activating
genes
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002349784A
Other versions
AU2002349784A1 (en
Inventor
Shuji Muramatsu
Akio Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001368692A external-priority patent/JP2006166701A/en
Priority claimed from JP2002291302A external-priority patent/JP2006166705A/en
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of AU2002349784A8 publication Critical patent/AU2002349784A8/en
Publication of AU2002349784A1 publication Critical patent/AU2002349784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002349784A 2001-12-03 2002-12-03 Nf-kappab activating genes Abandoned AU2002349784A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2001-368692 2001-12-03
JP2001368692A JP2006166701A (en) 2001-12-03 2001-12-03 NF-kappaB ACTIVATING GENE
US33582901P 2001-12-05 2001-12-05
US60/335,829 2001-12-05
JP2002291302A JP2006166705A (en) 2002-10-03 2002-10-03 NF-kappaB ACTIVATING GENE
JP2002-291302 2002-10-03
US41576902P 2002-10-04 2002-10-04
US60/415,769 2002-10-04
PCT/JP2002/012644 WO2003048202A2 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Publications (2)

Publication Number Publication Date
AU2002349784A8 true AU2002349784A8 (en) 2003-06-17
AU2002349784A1 AU2002349784A1 (en) 2003-06-17

Family

ID=27482716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002349784A Abandoned AU2002349784A1 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Country Status (2)

Country Link
AU (1) AU2002349784A1 (en)
WO (1) WO2003048202A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
AU2003245990A1 (en) * 2002-06-26 2004-01-19 Bayer Healthcare Ag Regulation of human map kinase kinase kinase
AU2003301621A1 (en) * 2002-10-22 2004-05-13 Oregon Health And Science University Apoptotic response regulation through interaction of tripartite motif protein 32 with pias
AU2003290432A1 (en) * 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
WO2004106937A2 (en) * 2003-06-02 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled p2y purinoreceptor 6 (p2y6)
EP1636258A2 (en) * 2003-06-10 2006-03-22 Xantos Biomedicine AG Angiogenic factor and inhibitors thereof
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
KR101200133B1 (en) 2004-06-01 2012-11-13 제넨테크, 인크. Antibody drug conjugates and methods
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2007054042A (en) * 2005-07-26 2007-03-08 Japan Science & Technology Agency Interferon-inducing molecule ips-1
WO2010017248A2 (en) * 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
WO2010053877A2 (en) * 2008-11-04 2010-05-14 The Regents Of The University Of Colorado, A Body Corporate Mhc ii associated protein and uses thereof
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
BR112012026213B1 (en) 2010-04-15 2021-12-28 Medimmune Limited PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CN103030688B (en) * 2011-09-30 2014-09-17 北京大学 Short chain polypeptide for inhibiting cancer cell growth as well as encoding gene and application of short chain polypeptide
KR101877598B1 (en) 2011-10-14 2018-07-11 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
ES2703151T3 (en) 2012-10-12 2019-03-07 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
PT2839860T (en) 2012-10-12 2019-07-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EA031585B1 (en) 2012-12-21 2019-01-31 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
CN105246894A (en) 2012-12-21 2016-01-13 斯皮罗根有限公司 Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
AU2014307080B2 (en) 2013-08-12 2018-06-07 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
JP6895254B2 (en) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and their antibodies-drug conjugates
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
MA40575A (en) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
RS61795B1 (en) 2017-02-08 2021-06-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc.
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (en) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical decomposition inducers and usage
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4311835A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Method for inhibiting gene transcription
GB9424497D0 (en) * 1994-12-05 1995-01-25 Karobio Ab Reporter cell line
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
JPH11266872A (en) * 1998-03-20 1999-10-05 Suntory Ltd Screening of substance suppressing activation of nf-kappa b
SE0001071D0 (en) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines

Also Published As

Publication number Publication date
WO2003048202A2 (en) 2003-06-12
WO2003048202A3 (en) 2004-07-01
AU2002349784A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
AU2002349784A8 (en) Nf-kappab activating genes
EP1360093A4 (en) Airbag
HK1049312A1 (en) Writing implement
AU2002357860A8 (en) Enzymes
GB0129923D0 (en) Writing implement
EP1353546A4 (en) Specification
GB0128180D0 (en) Bioremediation
DE50204556D1 (en) Airbag
AU6424701A (en) Gasc1 gene
GB0122232D0 (en) Gene expression
HK1058651A1 (en) Writing implement
GB0104440D0 (en) Novel genes
GB0108110D0 (en) Keeps
GB0109008D0 (en) Novel genes
GB0107360D0 (en) Genes
GB0107234D0 (en) Genes
GB0125757D0 (en) Genes
GB0124037D0 (en) Genes
GB0120558D0 (en) Genes
GB0130796D0 (en) Genes
GB0126030D0 (en) Gene expression
GB0128769D0 (en) Gene
GB0116360D0 (en) Gene PRPC8
GB0122730D0 (en) Gene Linkakge
GB0115709D0 (en) Novel genes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase